Full text is available at the source.
Many GLP-1 Drugs: How to Choose and When to Use Them
Updated
Abstract
Six Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are approved for treating type 2 diabetes.
- All approved GLP-1RAs lower hemoglobin A1C (HbA1C) levels.
- Short-acting GLP-1RAs include exenatide, liraglutide, and lixisenatide.
- Long-acting GLP-1RAs are administered weekly and include exenatide, albiglutide, and dulaglutide.
- Distinct features of GLP-1RAs affect weight loss, glucose control, cardiovascular safety, and side effects.
- Patient-specific characteristics should guide the selection of a GLP-1RA.
Simplified